Spongiform hemangioma is the most common benign tumor of the liver, and hepatic artery embolization, especially sclerosing embolization, has so far become an important treatment for hepatic cavernous hemangioma due to its reliable efficacy and few treatment complications. Anhydrous ethanol has been widely used in clinical practice as an effective permanent embolic agent. The author applied anhydrous ethanol and super-liquefied iodized oil in the ratio of 2:1 to form an emulsion, and achieved satisfactory results in 25 cases of hepatic hemangioma treated with transcatheter intravascular embolization, which is reported below. Spongiform hemangioma is the most common benign tumor of the liver, with an autopsy incidence of 0.4% to 7.0%. With the progress of diagnostic imaging technology, the number of cases of hepatic cavernous hemangioma is increasing day by day, and it can occur at any age, but it is more common in 30-50 years old, and more women than men. Hepatic cavernous hemangioma can be generally divided into three levels: (1) small cavernous hemangioma with a maximum diameter of <4 cm; (2) large cavernous hemangioma with a diameter of 5-10 cm; (3) those with a maximum diameter of >10 cm are called giant cavernous hemangioma. In larger cases, symptoms include abdominal mass, epigastric distension, vague pain in the liver area, occasional nausea, vomiting, obstructive jaundice, and gastric pyloric obstruction. Giant hepatic cavernous hemangiomas can sometimes present with varying degrees of anemia, thrombocytopenia, and hypofibrinogenemia. Mild anemia occurred in two patients and mild thrombocytopenia occurred in three patients in this group. Hepatic cavernous hemangiomas do not usually rupture spontaneously, but it is common for giant hepatic cavernous hemangiomas to have intra-tumoral hemorrhage or previous intra-tumoral hemorrhage, and the intra-tumoral hematoma may manifest as a cystic lesion within the hemangioma in the chronic phase. One case of hemangioma in this group developed shock due to internal hemorrhage. The majority of hepatic cavernous hemangiomas have no clinical symptoms and are found only on normal examination without treatment. The currently accepted indications include symptomatic hemangiomas, hemangiomas of 5 cm or more in diameter with enlarged lesions or risk of bleeding. Because of the large size of the hepatic giant cavernous hemangioma, the difficulty of surgical resection, and the mortality and uncontrollable bleeding associated with surgery, most patients are currently reluctant to undergo surgery, while transarterial embolization is less invasive, less reactive, and highly effective. The mechanism of treatment is that the hemangioma is mainly supplied by the hepatic artery, and embolization of the diseased supplying artery causes the lesion to shrink and the symptoms to be relieved. As a radical treatment for cavernous hemangioma, embolic agents are generally required to have a permanent embolic effect, both to completely fill the tumor vascular bed and to effectively prevent the establishment of collateral blood supply. Anhydrous ethanol is the most effective embolic agent. Theoretically, anhydrous ethanol has the strongest embolic effect, but because of its invisibility under fluoroscopy, it is often mixed with a certain amount of contrast agent such as iodized oil in clinical application so that it can be closely monitored during injection, and in order to prevent misembolization caused by reflux during injection, in addition, balloon catheter injection or microcatheter super-selective cannulation can be used to protect normal tissues as much as possible. The author had embolized 16 renal vascular smooth machine lipomas, of which 8 cases were embolized with anhydrous ethanol iodine oil (anhydrous ethanol: iodine oil = 2 to 3:1) and 8 cases were embolized with pinyamycin super-liquefied iodine oil emulsion, with a follow-up follow-up of 4 months to 5 years, mean 36.5 months, resulting in 5 patients requiring a second intervention, including 3 cases of pinyamycin super-liquefied iodine oil emulsion embolization, including 2 cases of rebleeding The embolization was followed by surgical resection. Based on this, in this study we used therefore anhydrous ethanol-iodine oil emulsion embolization (anhydrous ethanol: iodine oil = 2:1), which resulted in a maximum tumor diameter of 6.5 cm to 15.3 cm (8.15 ± 2.03 cm) in 25 patients, with significant tumor shrinkage at 6 and 12 months after embolization (5.3 ± 1.6 cm and 2.8 ± 1.2 cm, respectively), indicating a reliable treatment effect. The mechanism of embolization caused by anhydrous ethanol in target organs: (1) endothelial damage caused by contact between ethanol and vascular endothelial cells; (2) damage to the blood’s organic fraction and protein denaturation and precipitation; (3) alteration of the local blood rheological properties, i.e., spasmodic contraction and subsequent expansion of the vascular wall after stimulation by ethanol, expansion of blood from axial flow to side flow, and attachment of leukocytes and degraded proteins to the ethanol-damaged endothelium. (4) ethanol can penetrate directly or enter the tissue through the endothelial fissure to denature the tissue cells, resulting in the loss of enzyme system and protein biological activity; (5) micro thrombus formation in the blood vessel. The combination of iodinated oil and anhydrous ethanol has a mutually reinforcing effect, as the former prolongs the action of the latter, while the latter delays the clearance of the former in the foci, and the combination of the two is beneficial for x-ray follow-up, monitoring of the cinnamon process, and follow-up observation. As an embolic agent for hepatic cavernous hemangioma, the efficacy of anhydrous ethanol and iodinated oil emulsion depends on the embolization speed and embolization dose. If the embolization speed is too fast, the proximal vessels will be embolized first and the distal vessels and tumor body will be affected; if the speed is too slow, the ethanol will be diluted by blood and incomplete embolization will be formed easily. The dosage of embolic agent should be determined by factors such as too small tumor and rich blood supply. The author experiences that the embolization speed should be determined according to the depth of the catheter, the size of the target vessel in the anterior segment of the catheter and the hand-push contrast, and a speed of 0.2~0.5 ml/s is appropriate. If the diameter of the tumor is too large >20 cm, the tumor can be embolized in several times to achieve complete embolization of the tumor as much as possible: 5-25 ml of single embolization agent is appropriate, and the use of microcatheters is recommended if possible, because the blood supply arteries of cavernous hemangioma are often more twisted and thickened than those of primary hepatocellular carcinoma, especially the lack of blood, and it is often difficult to avoid the normal vascular branches, especially the gallbladder artery and the right gastric artery. gallbladder artery, right gastric artery, etc., and sometimes may cause spasm and entrapment of the responsible artery, which can more effectively embolize the tumor, protect normal tissues, reduce postoperative adverse effects and shorten the hospital stay. All the cases in this group were treated with microcatheters, and the postoperative adverse effects were mild. Except for 3 cases with huge lesions, the maximum diameter of which exceeded 15 cm, and the presence of hepatic artery portal fistula in the lesion area for 2 embolization treatments, all the cases were successfully treated in 1 time. Therefore, the author believes that embolization of hepatic hemangioma with a volume ratio of 2:1 anhydrous ethanol to iodized oil emulsion is an effective, convenient and safe method.